Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline receives UK approval for Combodart

GlaxoSmithKline receives UK approval for Combodart

6th May 2010

GlaxoSmithKline has been granted a licence approval for Combodart, a new treatment for moderate-to-severe benign prostatic hyperplasia (BPH).

The therapy, which is a combination of dutasteride and tamsulosin hydrochloride, has been approved on the basis of results from a four-year clinical study, which showed its efficacy in reducing the risk of urinary retention and BPH-related surgery.

It is the first treatment to be approved in the UK which combines the positive effects of two separate recommended monotherapies.

Dr Jon Rees, a GP from Bristol with a special interest in urology, said the effectiveness of the treatment makes it more likely that patients will stick to medication regimes and avoid disease progression.

He added: “By delivering all the advantages of two treatments in one single capsule, the arrival of Combodart represents a new approach to BPH management in the UK.”

Last week, GlaxoSmithKline published its financial report for the first quarter of 2010, reporting a year-on-year turnover increase of 13 per cent.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.